In an interview with BioSpectrum Asia, Novotech CEO Dr John Moller provides his thoughts on the state of Australia's medical technologies, biotechnology and pharmaceutical (MTP) sector. 

BioSpectrum Asia: Australia - A thriving lifescience hub with a global reach 
20 October 2017, by Aishwarya Venkatesh

In other News

March 14, 2023 News

Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report

Singapore - Novotech, the leading Asia Pacific centred biotech CRO has published

Read more
March 7, 2023 News

Novotech Team at BIO Europe to Share Benefits of Expanded Global Operations

Singapore - Novotech, the leading Asia Pacific centred biotech CRO will be at BI

Read more
March 3, 2023 News

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trial

Read more
February 10, 2023 News

Global Report: Robust Phase 1 Trial Growth Across Asia Pacific

Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phas

Read more
February 2, 2023 News

Asia Pacific Cell & Gene Research Growing 50% Faster than ROW

Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the

Read more
January 10, 2023 News

Novotech Acquires US-based Drug Development Consulting Firm, CBR International - Expands Drug…

Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR In

Read more
More News Articles

Other relevant content